Drug intelligence / Profile preview

FF-31501

Development stage: Phase 3
Lead developer: FUJIFILM Toyama Chemical
Modality: Recombinant Proteins and Enzymes
Administration: Intraarticular

Overview

FF-31501 is a recombinant human stromal cell-derived factor-1 (SDF-1, also known as CXCL12) being developed by FUJIFILM Toyama Chemical for the treatment of meniscus tears. Administered via intra-articular injection, the drug functions as a chemoattractant to recruit endogenous mesenchymal stem cells (MSCs) to the site of the tear, thereby promoting the natural healing and regeneration of the meniscus tissue. It is currently in Phase 3 clinical trials in Japan for patients eligible for meniscectomy, aiming to improve knee joint function and potentially avoid the need for surgical removal of the meniscus.

Other names: recombinant human stromal cell-derived factor-1rhSDF-1rhSDF1rhSDF 1CXCL12CXCL-12CXCL 12

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on FF-31501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FF-31501.

Explore the full profile